# Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC

Source: https://onco.cc/trials/nct07291401/  
OnCo record `nct07291401` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Zhongnan Hospital, now recruiting.

## Summary

Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC is a phase 2, interventional study registered as NCT07291401 by Zhongnan Hospital, with a registry enrolment figure of 108 participants, started 2025-11-01 and due to reach its primary completion in 2027-01-01. Interventions recorded: lparomlimab and Tuvonralimab Injection and CPAOX and radiotherapy. Conditions listed: Rectal Cancer Patients. Primary outcome: Complete response (CR). Colorectal eligibility wording from the registry: "* (1) The patient is histologically diagnosed with rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07291401
- Phase: 2
- Setting: Neoadjuvant Chemoradiotherapy Combined Cith Iparomlimab and Tuvonralimab (QL1706) Therapy for Locally Advanced Rectal Cancer：a Single-center, Prospective, Single-arm, Open-label, Phase II Clinical Trial
- Sponsor: Zhongnan Hospital
- Enrolled: 108

## Sources

- ClinicalTrials.gov NCT07291401: https://clinicaltrials.gov/study/NCT07291401

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07291401.json